SCHEMBL4833481

SCHEMBL4833481

c1cc2cc(NC3CC3)ccc2[nH]1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.54
RAB9A P51151 3/20 0.54
MAPT P10636 2/20 0.54
EPHX1 P07099 1/20 0.54
ULK1 O75385 1/20 0.53
SYK P43405 1/20 0.51
S1PR1 P21453 1/20 0.48
ROCK2 O75116 2/20 0.47
MAOB P27338 4/20 0.46
MAOA P21397 3/20 0.46
AHR P35869 3/20 0.44
NR4A2 P43354 2/20 0.44
CYP2A6 P11509 1/20 0.44
F7 P08709 1/20 0.44
LTA4H P09960 1/20 0.44
F3 P13726 1/20 0.44
USP2 O75604 1/20 0.44
GAA P10253 1/20 0.44
ALOX15 P16050 1/20 0.44
RAD51 Q06609 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3840654 0.92 MAPT (0.64) NPC1RAB9AMAPTEPHX1ULK1
SCHEMBL1082254 0.90 NPC1 (0.49) NPC1RAB9AMAPTEPHX1ULK1
SCHEMBL4994830 0.83 HRH3 (0.56) NPC1RAB9AMAPTEPHX1ULK1
SCHEMBL10102883 0.81 EPHX1 (0.44) NPC1RAB9AMAPTEPHX1ULK1
SCHEMBL5164013 0.78 OPRL1 (0.46) NPC1RAB9AMAPTEPHX1MAOB
SCHEMBL25834155 0.77 KIT (0.52) ROCK2ROCK1
SCHEMBL312970 0.76 KDM4E (0.60) MAPTROCK2MAOAUSP2GAA
SCHEMBL17539396 0.75 VCP (0.47) NPC1RAB9AMAPTEPHX1MAOB
SCHEMBL12129516 0.74 SYK (0.50) NPC1RAB9AMAPTEPHX1SYK
SCHEMBL19654392 0.74 ULK1 (0.72) ULK1SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7446199-B2 Compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-11-04 US disclosed
EP-1664043-B1 COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMA (US) 2007-11-14 EP disclosed
EP-1664043-A2 COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES Vertex Pharmaceuticals Incorporated (US) 2006-06-07 EP disclosed
US-20050137201-A1 Compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED 2005-06-23 US disclosed
WO-2005028475-A2 COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2005-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137201-A1 Compositions useful as inhibitors of protein kinases MAP3K20, PACSIN2, MAP3K6 NPC1 2409/4885RAB9A 1904/4885MAPT 1133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.